Australian Broker Call *Extra* Edition – Oct 07, 2025

Array
(
    [0] => Array
        (
            [0] => ((ABB))
            [1] => ((ACL))
            [2] => ((AQZ))
            [3] => ((ASG))
            [4] => ((AVH))
            [5] => ((BVS))
            [6] => ((CKF))
            [7] => ((COH))
            [8] => ((CSL))
            [9] => ((CUV))
            [10] => ((DTL))
            [11] => ((ELD))
            [12] => ((EQT))
            [13] => ((FPH))
            [14] => ((GNC))
            [15] => ((IPD))
            [16] => ((IRE))
            [17] => ((JAN))
            [18] => ((M7T))
            [19] => ((MGH))
            [20] => ((MVF))
            [21] => ((NCK))
            [22] => ((PLT))
            [23] => ((PME))
            [24] => ((PNC))
            [25] => ((PNI))
            [26] => ((PNV))
            [27] => ((RDY))
            [28] => ((RFF))
            [29] => ((RHC))
            [30] => ((RIC))
            [31] => ((RMD))
            [32] => ((RWL))
            [33] => ((SDR))
            [34] => ((SHV))
            [35] => ((SKS))
            [36] => ((SOM))
            [37] => ((TLX))
            [38] => ((TNE))
            [39] => ((VYS))
        )

    [1] => Array
        (
            [0] => ABB
            [1] => ACL
            [2] => AQZ
            [3] => ASG
            [4] => AVH
            [5] => BVS
            [6] => CKF
            [7] => COH
            [8] => CSL
            [9] => CUV
            [10] => DTL
            [11] => ELD
            [12] => EQT
            [13] => FPH
            [14] => GNC
            [15] => IPD
            [16] => IRE
            [17] => JAN
            [18] => M7T
            [19] => MGH
            [20] => MVF
            [21] => NCK
            [22] => PLT
            [23] => PME
            [24] => PNC
            [25] => PNI
            [26] => PNV
            [27] => RDY
            [28] => RFF
            [29] => RHC
            [30] => RIC
            [31] => RMD
            [32] => RWL
            [33] => SDR
            [34] => SHV
            [35] => SKS
            [36] => SOM
            [37] => TLX
            [38] => TNE
            [39] => VYS
        )

)

This story features AUSSIE BROADBAND LIMITED, and other companies.
For more info SHARE ANALYSIS: ABB
The company is included in ASX200, ASX300 and ALL-ORDS

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

ABB   ACL   AQZ   ASG   AVH   BVS   CKF   COH   CSL   CUV   DTL   ELD   EQT   FPH   GNC   IPD   IRE   JAN   M7T   MGH   MVF   NCK   PLT   PME   PNC   PNI   PNV   RDY   RFF   RHC   RIC   RMD   RWL   SDR   SHV   SKS   SOM   TLX   TNE   VYS  

ABB    AUSSIE BROADBAND LIMITED

Telecommunication – Overnight Price: $5.87

Canaccord Genuity rates ((ABB)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Cameron Bell will take over coverage of Aussie Broadband.

Buy. Target Price $6.85.

This report was published on October 3, 2025.

Target price is $6.85 Current Price is $5.87 Difference: $0.98
If ABB meets the Canaccord Genuity target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $5.95, suggesting upside of 1.4%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 6.30 cents and EPS of 18.10 cents.
At the last closing share price the estimated dividend yield is 1.07%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 32.43.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 18.8, implying annual growth of 68.0%.
Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 31.2.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 10.60 cents and EPS of 26.50 cents.
At the last closing share price the estimated dividend yield is 1.81%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.15.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 25.4, implying annual growth of 35.1%.
Current consensus DPS estimate is 8.1, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 23.1.

Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ACL    AUSTRALIAN CLINICAL LABS LIMITED

Healthcare services – Overnight Price: $2.50

Canaccord Genuity rates ((ACL)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Australian Clinical Labs continues to be covered by Shane Storey.

Buy. Target Price $3.85.

This report was published on October 3, 2025.

Target price is $3.85 Current Price is $2.50 Difference: $1.35
If ACL meets the Canaccord Genuity target it will return approximately 54% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 11.40 cents and EPS of 19.00 cents.
At the last closing share price the estimated dividend yield is 4.56%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.16.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 13.20 cents and EPS of 22.00 cents.
At the last closing share price the estimated dividend yield is 5.28%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.36.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

AQZ    ALLIANCE AVIATION SERVICES LIMITED

Transportation & Logistics – Overnight Price: $2.16

Canaccord Genuity rates ((AQZ)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Alliance Aviation Services continues to be covered by James Ferrier.

Buy. Target Price $2.58.

This report was published on October 3, 2025.

Target price is $2.58 Current Price is $2.16 Difference: $0.42
If AQZ meets the Canaccord Genuity target it will return approximately 19% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 12.30 cents and EPS of 35.10 cents.
At the last closing share price the estimated dividend yield is 5.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.15.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 16.60 cents and EPS of 33.30 cents.
At the last closing share price the estimated dividend yield is 7.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.49.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ASG    AUTOSPORTS GROUP LIMITED

Automobiles & Components – Overnight Price: $3.22

Canaccord Genuity rates ((ASG)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Autosports Group continues to be covered by James Ferrier.

Buy. Target Price $3.51.

This report was published on October 3, 2025.

Target price is $3.51 Current Price is $3.22 Difference: $0.29
If ASG meets the Canaccord Genuity target it will return approximately 9% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 15.20 cents and EPS of 25.30 cents.
At the last closing share price the estimated dividend yield is 4.72%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.73.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 20.80 cents and EPS of 34.70 cents.
At the last closing share price the estimated dividend yield is 6.46%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.28.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

AVH    AVITA MEDICAL INC

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $1.66

Canaccord Genuity rates ((AVH)) as Sell (5) –

Following Canaccord Genuity’s acquisition of Wilsons, Avita Medical continues to be covered by Shane Storey.

Sell. Target Price $1.25.

This report was published on October 3, 2025.

Target price is $1.25 Current Price is $1.66 Difference: minus $0.41 (current price is over target).
If AVH meets the Canaccord Genuity target it will return approximately minus 25% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in December.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 32.95 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 5.04.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 16.94 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 9.80.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

BVS    BRAVURA SOLUTIONS LIMITED

Wealth Management & Investments – Overnight Price: $3.35

Canaccord Genuity rates ((BVS)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Bravura Solutions continues to be covered by Cameron Halkett.

Hold. Target Price $2.10.

This report was published on October 3, 2025.

Target price is $2.10 Current Price is $3.35 Difference: minus $1.25 (current price is over target).
If BVS meets the Canaccord Genuity target it will return approximately minus 37% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 4.60 cents and EPS of 7.50 cents.
At the last closing share price the estimated dividend yield is 1.37%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 44.67.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 5.00 cents and EPS of 8.20 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 40.85.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CKF    COLLINS FOODS LIMITED

Food, Beverages & Tobacco – Overnight Price: $10.69

Canaccord Genuity rates ((CKF)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, coverage of Collins Foods is transferred to James Ferrier.

Buy. Target Price $12.23 (was $10.85 when Canaccord Genuity last covered the stock).

This report was published on October 3, 2025.

Target price is $12.23 Current Price is $10.69 Difference: $1.54
If CKF meets the Canaccord Genuity target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $10.11, suggesting downside of -5.4%(ex-dividends)
The company’s fiscal year ends in April.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 32.00 cents and EPS of 53.20 cents.
At the last closing share price the estimated dividend yield is 2.99%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.09.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 48.7, implying annual growth of 549.3%.
Current consensus DPS estimate is 27.6, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 22.0.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 39.00 cents and EPS of 64.70 cents.
At the last closing share price the estimated dividend yield is 3.65%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.52.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 57.7, implying annual growth of 18.5%.
Current consensus DPS estimate is 32.5, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 18.5.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

COH    COCHLEAR LIMITED

Medical Equipment & Devices – Overnight Price: $284.80

Canaccord Genuity rates ((COH)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Cochlear continues to be covered by Shane Storey.

Hold. Target Price $330.

This report was published on October 3, 2025.

Target price is $330.00 Current Price is $284.80 Difference: $45.2
If COH meets the Canaccord Genuity target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $306.74, suggesting upside of 7.7%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 460.00 cents and EPS of 664.80 cents.
At the last closing share price the estimated dividend yield is 1.62%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 42.84.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 690.5, implying annual growth of 16.2%.
Current consensus DPS estimate is 493.8, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 41.2.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 510.00 cents and EPS of 739.80 cents.
At the last closing share price the estimated dividend yield is 1.79%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 38.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 785.4, implying annual growth of 13.7%.
Current consensus DPS estimate is 561.6, implying a prospective dividend yield of 2.0%.
Current consensus EPS estimate suggests the PER is 36.3.

Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CSL    CSL LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $205.67

Canaccord Genuity rates ((CSL)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, CSL continues to be covered by Shane Storey.

Hold. Target Price $227.50.

This report was published on October 3, 2025.

Target price is $227.50 Current Price is $205.67 Difference: $21.83
If CSL meets the Canaccord Genuity target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $276.82, suggesting upside of 34.6%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 474.04 cents and EPS of 1085.17 cents.
At the last closing share price the estimated dividend yield is 2.30%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.95.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 1052.3, implying annual growth of N/A.
Current consensus DPS estimate is 496.6, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 19.5.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 507.93 cents and EPS of 1175.47 cents.
At the last closing share price the estimated dividend yield is 2.47%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 1227.1, implying annual growth of 16.6%.
Current consensus DPS estimate is 545.7, implying a prospective dividend yield of 2.7%.
Current consensus EPS estimate suggests the PER is 16.8.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CUV    CLINUVEL PHARMACEUTICALS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $12.62

Canaccord Genuity rates ((CUV)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, coverage of Clinuvel Pharmaceuticals is transferred to Madeleine Williams.

Buy. Target Price $32.84.

Forecasts are under review.

This report was published on October 3, 2025.

Target price is $32.84 Current Price is $12.62 Difference: $20.22
If CUV meets the Canaccord Genuity target it will return approximately 160% (excluding dividends, fees and charges).
Current consensus price target is $18.53, suggesting upside of 46.9%(ex-dividends)

Forecast for FY26:

Current consensus EPS estimate is 69.8, implying annual growth of -3.4%.
Current consensus DPS estimate is 5.5, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 18.1.

Forecast for FY27:

Current consensus EPS estimate is 69.5, implying annual growth of -0.4%.
Current consensus DPS estimate is 6.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 18.2.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

DTL    DATA#3 LIMITED.

IT & Support – Overnight Price: $9.19

Canaccord Genuity rates ((DTL)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Data#3 continues to be covered by Cameron Halkett.

Hold. Target Price $8.67.

This report was published on October 3, 2025.

Target price is $8.67 Current Price is $9.19 Difference: minus $0.52 (current price is over target).
If DTL meets the Canaccord Genuity target it will return approximately minus 6% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $8.76, suggesting downside of -4.7%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 30.40 cents and EPS of 33.10 cents.
At the last closing share price the estimated dividend yield is 3.31%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.76.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 33.2, implying annual growth of 6.7%.
Current consensus DPS estimate is 29.0, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 27.7.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 32.00 cents and EPS of 35.20 cents.
At the last closing share price the estimated dividend yield is 3.48%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 26.11.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 37.0, implying annual growth of 11.4%.
Current consensus DPS estimate is 32.9, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 24.8.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ELD    ELDERS LIMITED

Agriculture – Overnight Price: $7.38

Canaccord Genuity rates ((ELD)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Elders continues to be covered by James Ferrier.

Buy. Target Price $8.22.

This report was published on October 3, 2025.

Target price is $8.22 Current Price is $7.38 Difference: $0.84
If ELD meets the Canaccord Genuity target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $8.83, suggesting upside of 19.7%(ex-dividends)
The company’s fiscal year ends in September.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 36.00 cents and EPS of 53.70 cents.
At the last closing share price the estimated dividend yield is 4.88%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.74.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 50.7, implying annual growth of 79.7%.
Current consensus DPS estimate is 36.0, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 14.6.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 36.00 cents and EPS of 57.90 cents.
At the last closing share price the estimated dividend yield is 4.88%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.75.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 62.1, implying annual growth of 22.5%.
Current consensus DPS estimate is 38.5, implying a prospective dividend yield of 5.2%.
Current consensus EPS estimate suggests the PER is 11.9.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

EQT    EQT HOLDINGS LIMITED

Diversified Financials – Overnight Price: $23.20

Canaccord Genuity rates ((EQT)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, EQT Holdings continues to be covered by Cameron Halkett.

Buy. Target Price $37.

This report was published on October 3, 2025.

Target price is $37.00 Current Price is $23.20 Difference: $13.8
If EQT meets the Canaccord Genuity target it will return approximately 59% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 117.00 cents and EPS of 168.30 cents.
At the last closing share price the estimated dividend yield is 5.04%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.78.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 122.00 cents and EPS of 181.60 cents.
At the last closing share price the estimated dividend yield is 5.26%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.78.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

FPH    FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

Medical Equipment & Devices – Overnight Price: $33.22

Canaccord Genuity rates ((FPH)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Fisher & Paykel Healthcare continues to be covered by Shane Storey.

Buy. Target Price $37.58.

This report was published on October 3, 2025.

Target price is $37.58 Current Price is $33.22 Difference: $4.36
If FPH meets the Canaccord Genuity target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is N/A
The company’s fiscal year ends in March.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 43.69 cents and EPS of 65.53 cents.
At the last closing share price the estimated dividend yield is 1.32%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 50.69.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 64.3, implying annual growth of N/A.
Current consensus DPS estimate is 41.0, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 51.7.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 49.15 cents and EPS of 75.27 cents.
At the last closing share price the estimated dividend yield is 1.48%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 44.13.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 76.1, implying annual growth of 18.4%.
Current consensus DPS estimate is 47.3, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 43.7.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

GNC    GRAINCORP LIMITED

Agriculture – Overnight Price: $9.04

Canaccord Genuity rates ((GNC)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, GrainCorp continues to be covered by James Ferrier.

Buy. Target Price $9.05.

This report was published on October 3, 2025.

Target price is $9.05 Current Price is $9.04 Difference: $0.01
If GNC meets the Canaccord Genuity target it will return approximately 0% (excluding dividends, fees and charges).
Current consensus price target is $9.00, suggesting downside of -0.4%(ex-dividends)
The company’s fiscal year ends in September.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 48.00 cents and EPS of 34.00 cents.
At the last closing share price the estimated dividend yield is 5.31%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 26.59.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 39.8, implying annual growth of 43.9%.
Current consensus DPS estimate is 43.8, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 22.7.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 54.00 cents and EPS of 59.00 cents.
At the last closing share price the estimated dividend yield is 5.97%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.32.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 49.4, implying annual growth of 24.1%.
Current consensus DPS estimate is 41.6, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 18.3.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

IPD    IMPEDIMED LIMITED

Medical Equipment & Devices – Overnight Price: $0.05

Canaccord Genuity rates ((IPD)) as Speculative Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, coverage of ImpediMed is transferred to Shane Storey.

Speculative Buy. Target Price 7c (was 9c when Canaccord Genuity last covered the stock).

This report was published on October 3, 2025.

Target price is $0.07 Current Price is $0.05 Difference: $0.02
If IPD meets the Canaccord Genuity target it will return approximately 40% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 7.14.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.00.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

IRE    IRESS LIMITED

Wealth Management & Investments – Overnight Price: $8.70

Canaccord Genuity rates ((IRE)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Iress continues to be covered by Cameron Halkett.

Buy. Target Price $10.

This report was published on October 3, 2025.

Target price is $10.00 Current Price is $8.70 Difference: $1.3
If IRE meets the Canaccord Genuity target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $9.73, suggesting upside of 11.8%(ex-dividends)
The company’s fiscal year ends in December.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 35.00 cents and EPS of 35.20 cents.
At the last closing share price the estimated dividend yield is 4.02%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.72.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 35.5, implying annual growth of -26.0%.
Current consensus DPS estimate is 21.1, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 24.5.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 41.00 cents and EPS of 40.20 cents.
At the last closing share price the estimated dividend yield is 4.71%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.64.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 39.2, implying annual growth of 10.4%.
Current consensus DPS estimate is 23.8, implying a prospective dividend yield of 2.7%.
Current consensus EPS estimate suggests the PER is 22.2.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

JAN    JANISON EDUCATION GROUP LIMITED

Education & Tuition – Overnight Price: $0.22

Canaccord Genuity rates ((JAN)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Janison Education continues to be covered by Cameron Halkett.

Hold. Target Price $0.21.

This report was published on October 3, 2025.

Target price is $0.21 Current Price is $0.22 Difference: minus $0.01 (current price is over target).
If JAN meets the Canaccord Genuity target it will return approximately minus 5% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 8.80.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.48.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

M7T    MACH7 TECHNOLOGIES LIMITED

Healthcare services – Overnight Price: $0.32

Canaccord Genuity rates ((M7T)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Mach7 Technologies continues to be covered by Shane Storey.

Buy. Target Price $0.85.

This report was published on October 3, 2025.

Target price is $0.85 Current Price is $0.32 Difference: $0.53
If M7T meets the Canaccord Genuity target it will return approximately 166% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 32.00.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 64.00.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

MGH    MAAS GROUP HOLDINGS LIMITED

Building Products & Services – Overnight Price: $4.42

Canaccord Genuity rates ((MGH)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Maas Group continues to be covered by James Ferrier.

Buy. Target Price $4.74.

This report was published on October 3, 2025.

Target price is $4.74 Current Price is $4.42 Difference: $0.32
If MGH meets the Canaccord Genuity target it will return approximately 7% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 10.00 cents and EPS of 28.30 cents.
At the last closing share price the estimated dividend yield is 2.26%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.62.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 12.00 cents and EPS of 35.80 cents.
At the last closing share price the estimated dividend yield is 2.71%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.35.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

MVF    MONASH IVF GROUP LIMITED

Healthcare services – Overnight Price: $0.69

Canaccord Genuity rates ((MVF)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Monash IVF continues to be covered by Shane Storey.

Hold. Target Price $0.72.

This report was published on October 3, 2025.

Target price is $0.72 Current Price is $0.69 Difference: $0.025
If MVF meets the Canaccord Genuity target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $0.92, suggesting upside of 32.4%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 3.50 cents and EPS of 5.00 cents.
At the last closing share price the estimated dividend yield is 5.04%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.90.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 5.3, implying annual growth of -17.4%.
Current consensus DPS estimate is 3.1, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 13.1.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 3.70 cents and EPS of 5.30 cents.
At the last closing share price the estimated dividend yield is 5.32%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.11.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 5.9, implying annual growth of 11.3%.
Current consensus DPS estimate is 3.9, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 11.8.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

NCK    NICK SCALI LIMITED

Furniture & Renovation – Overnight Price: $22.84

Canaccord Genuity rates ((NCK)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Nick Scali continues to be covered by James Ferrier.

Hold. Target Price $20.40.

This report was published on October 3, 2025.

Target price is $20.40 Current Price is $22.84 Difference: minus $2.44 (current price is over target).
If NCK meets the Canaccord Genuity target it will return approximately minus 11% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $21.43, suggesting downside of -6.2%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 67.80 cents and EPS of 84.70 cents.
At the last closing share price the estimated dividend yield is 2.97%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 26.97.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.6, implying annual growth of 29.8%.
Current consensus DPS estimate is 67.2, implying a prospective dividend yield of 2.9%.
Current consensus EPS estimate suggests the PER is 26.1.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 83.20 cents and EPS of 104.00 cents.
At the last closing share price the estimated dividend yield is 3.64%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.96.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 104.5, implying annual growth of 19.3%.
Current consensus DPS estimate is 80.4, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 21.9.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PLT    PLENTI GROUP LIMITED

Business & Consumer Credit – Overnight Price: $1.57

Canaccord Genuity rates ((PLT)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Plenti Group continues to be covered by Lachlan Woods.

Buy. Target Price $1.44.

This report was published on October 3, 2025.

Target price is $1.44 Current Price is $1.57 Difference: minus $0.13 (current price is over target).
If PLT meets the Canaccord Genuity target it will return approximately minus 8% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in March.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 12.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.98.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.27.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PME    PRO MEDICUS LIMITED

Medical Equipment & Devices – Overnight Price: $304.22

Canaccord Genuity rates ((PME)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Pro Medicus continues to be covered by Shane Storey.

Buy. Target Price $350.

This report was published on October 3, 2025.

Target price is $350.00 Current Price is $304.22 Difference: $45.78
If PME meets the Canaccord Genuity target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $321.93, suggesting upside of 5.8%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 74.30 cents and EPS of 150.30 cents.
At the last closing share price the estimated dividend yield is 0.24%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 202.41.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 153.0, implying annual growth of 38.7%.
Current consensus DPS estimate is 76.6, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 198.8.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 102.50 cents and EPS of 205.00 cents.
At the last closing share price the estimated dividend yield is 0.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 148.40.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 202.3, implying annual growth of 32.2%.
Current consensus DPS estimate is 107.7, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 150.4.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PNC    PIONEER CREDIT LIMITED

Business & Consumer Credit – Overnight Price: $0.61

Canaccord Genuity rates ((PNC)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Pioneer Credit continues to be covered by Lachlan Woods.

Buy. Target Price $0.87.

This report was published on October 3, 2025.

Target price is $0.87 Current Price is $0.61 Difference: $0.26
If PNC meets the Canaccord Genuity target it will return approximately 43% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 11.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.30.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 4.96.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PNI    PINNACLE INVESTMENT MANAGEMENT GROUP LIMITED

Wealth Management & Investments – Overnight Price: $18.55

Canaccord Genuity rates ((PNI)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Pinnacle Investment Management continues to be covered by Cameron Halkett.

Buy. Target Price $26.12.

This report was published on October 3, 2025.

Target price is $26.12 Current Price is $18.55 Difference: $7.57
If PNI meets the Canaccord Genuity target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $24.23, suggesting upside of 30.6%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 70.00 cents and EPS of 66.60 cents.
At the last closing share price the estimated dividend yield is 3.77%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.85.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 68.3, implying annual growth of 8.1%.
Current consensus DPS estimate is 60.8, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 27.2.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 81.00 cents and EPS of 81.40 cents.
At the last closing share price the estimated dividend yield is 4.37%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.79.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 82.6, implying annual growth of 20.9%.
Current consensus DPS estimate is 73.7, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 22.5.

Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PNV    POLYNOVO LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $1.54

Canaccord Genuity rates ((PNV)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, coverage of PolyNovo is transferred to Elyse Shapiro.

Buy. Target Price $1.62.

This report was published on October 3, 2025.

Target price is $1.62 Current Price is $1.54 Difference: $0.08
If PNV meets the Canaccord Genuity target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $1.90, suggesting upside of 23.2%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 77.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.3, implying annual growth of 20.4%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 67.0.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 45.29.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 3.9, implying annual growth of 69.6%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 39.5.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RDY    READYTECH HOLDINGS LIMITED

Software & Services – Overnight Price: $2.19

Canaccord Genuity rates ((RDY)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, ReadyTech Holdings continues to be covered by Cameron Halkett.

Hold. Target Price $2.63.

This report was published on October 3, 2025.

Target price is $2.63 Current Price is $2.19 Difference: $0.44
If RDY meets the Canaccord Genuity target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $3.35, suggesting upside of 53.1%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 13.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.76.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 7.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 30.0.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 17.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.73.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.0, implying annual growth of 50.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 19.9.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RFF    RURAL FUNDS GROUP

REITs – Overnight Price: $1.94

Canaccord Genuity rates ((RFF)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Rural Funds continues to be covered by James Ferrier.

Buy. Target Price $2.43.

This report was published on October 3, 2025.

Target price is $2.43 Current Price is $1.94 Difference: $0.49
If RFF meets the Canaccord Genuity target it will return approximately 25% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 11.70 cents and EPS of 11.70 cents.
At the last closing share price the estimated dividend yield is 6.03%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.58.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 12.20 cents and EPS of 12.50 cents.
At the last closing share price the estimated dividend yield is 6.29%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.52.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RHC    RAMSAY HEALTH CARE LIMITED

Healthcare services – Overnight Price: $31.83

Canaccord Genuity rates ((RHC)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Australian Clinical Labs continues to be covered by Shane Storey.

Hold. Target Price $37.

This report was published on October 3, 2025.

Target price is $37.00 Current Price is $31.83 Difference: $5.17
If RHC meets the Canaccord Genuity target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $34.72, suggesting upside of 9.1%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 77.40 cents and EPS of 124.10 cents.
At the last closing share price the estimated dividend yield is 2.43%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.65.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 138.9, implying annual growth of 4592.6%.
Current consensus DPS estimate is 87.8, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 22.9.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 111.80 cents and EPS of 179.10 cents.
At the last closing share price the estimated dividend yield is 3.51%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.77.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 174.5, implying annual growth of 25.6%.
Current consensus DPS estimate is 110.0, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 18.2.

Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RIC    RIDLEY CORPORATION LIMITED

Agriculture – Overnight Price: $2.97

Canaccord Genuity rates ((RIC)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Ridley Corp continues to be covered by James Ferrier.

Buy. Target Price $3.48.

This report was published on October 3, 2025.

Target price is $3.48 Current Price is $2.97 Difference: $0.51
If RIC meets the Canaccord Genuity target it will return approximately 17% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 10.50 cents and EPS of 15.10 cents.
At the last closing share price the estimated dividend yield is 3.54%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.67.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 13.50 cents and EPS of 19.40 cents.
At the last closing share price the estimated dividend yield is 4.55%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.31.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RMD    RESMED INC

Medical Equipment & Devices – Overnight Price: $42.09

Canaccord Genuity rates ((RMD)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, ResMed continues to be covered by Shane Storey.

Buy. Target Price $50.

This report was published on October 3, 2025.

Target price is $50.00 Current Price is $42.09 Difference: $7.91
If RMD meets the Canaccord Genuity target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $49.07, suggesting upside of 16.6%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 38.08 cents and EPS of 170.50 cents.
At the last closing share price the estimated dividend yield is 0.90%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.69.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 168.0, implying annual growth of N/A.
Current consensus DPS estimate is 36.6, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 25.1.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 40.72 cents and EPS of 192.73 cents.
At the last closing share price the estimated dividend yield is 0.97%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.84.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 187.2, implying annual growth of 11.4%.
Current consensus DPS estimate is 39.3, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 22.5.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RWL    RUBICON WATER LIMITED

Industrial Sector Contractors & Engineers – Overnight Price: $0.15

Canaccord Genuity rates ((RWL)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Rubicon Water continues to be covered by James Ferrier.

Buy. Target Price $0.44.

This report was published on October 3, 2025.

Target price is $0.44 Current Price is $0.15 Difference: $0.29
If RWL meets the Canaccord Genuity target it will return approximately 193% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 50.00.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.38.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

SDR    SITEMINDER LIMITED

Travel, Leisure & Tourism – Overnight Price: $7.45

Canaccord Genuity rates ((SDR)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, SiteMinder continues to be covered by Cameron Halkett.

Hold. Target Price $7.

This report was published on October 3, 2025.

Target price is $7.00 Current Price is $7.45 Difference: minus $0.45 (current price is over target).
If SDR meets the Canaccord Genuity target it will return approximately minus 6% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $8.10, suggesting upside of 8.7%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7450.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -0.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 8.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 86.63.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 6.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 122.1.

Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

SHV    SELECT HARVESTS LIMITED

Agriculture – Overnight Price: $3.79

Canaccord Genuity rates ((SHV)) as Hold (3) –

Following Canaccord Genuity’s acquisition of Wilsons, Select Harvests continues to be covered by James Ferrier.

Hold. Target Price $4.02.

This report was published on October 3, 2025.

Target price is $4.02 Current Price is $3.79 Difference: $0.23
If SHV meets the Canaccord Genuity target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $5.47, suggesting upside of 44.2%(ex-dividends)
The company’s fiscal year ends in September.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 13.50 cents and EPS of 20.60 cents.
At the last closing share price the estimated dividend yield is 3.56%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.40.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 24.4, implying annual growth of 1867.7%.
Current consensus DPS estimate is 1.3, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 15.5.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 27.70 cents and EPS of 50.40 cents.
At the last closing share price the estimated dividend yield is 7.31%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.52.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 36.3, implying annual growth of 48.8%.
Current consensus DPS estimate is 9.0, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 10.4.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

SKS    SKS TECHNOLOGIES GROUP LIMITED

Technology – Overnight Price: $4.19

Canaccord Genuity rates ((SKS)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, coverage of SKS Technologies is transferred to Warren Jeffries.

Buy. Target Price $3.14.

This report was published on October 3, 2025.

Target price is $3.14 Current Price is $4.19 Difference: minus $1.05 (current price is over target).
If SKS meets the Canaccord Genuity target it will return approximately minus 25% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 7.40 cents and EPS of 16.50 cents.
At the last closing share price the estimated dividend yield is 1.77%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.39.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 8.40 cents and EPS of 18.70 cents.
At the last closing share price the estimated dividend yield is 2.00%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.41.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

SOM    SOMNOMED LIMITED

Medical Equipment & Devices – Overnight Price: $0.85

Canaccord Genuity rates ((SOM)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, SomnoMed continues to be covered by Shane Storey.

Buy. Target Price $1.00.

This report was published on October 3, 2025.

Target price is $1.00 Current Price is $0.85 Difference: $0.15
If SOM meets the Canaccord Genuity target it will return approximately 18% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 77.27.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 56.67.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

TLX    TELIX PHARMACEUTICALS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $15.31

Canaccord Genuity rates ((TLX)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, coverage of Telix Pharmaceuticals is transferred to Madeleine Williams.

Buy. Target Price $27.33.

This report was published on October 3, 2025.

Target price is $27.33 Current Price is $15.31 Difference: $12.02
If TLX meets the Canaccord Genuity target it will return approximately 79% (excluding dividends, fees and charges).
Current consensus price target is $28.40, suggesting upside of 85.5%(ex-dividends)
The company’s fiscal year ends in December.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 13.37 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 114.54.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -2.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 25.02 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 61.18.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 10.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 151.6.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

TNE    TECHNOLOGY ONE LIMITED

IT & Support – Overnight Price: $38.89

Canaccord Genuity rates ((TNE)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, TechnologyOne continues to be covered by Cameron Halkett.

Buy. Target Price $40.99.

This report was published on October 3, 2025.

Target price is $40.99 Current Price is $38.89 Difference: $2.1
If TNE meets the Canaccord Genuity target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $38.04, suggesting downside of -2.2%(ex-dividends)
The company’s fiscal year ends in September.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 24.00 cents and EPS of 43.00 cents.
At the last closing share price the estimated dividend yield is 0.62%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 90.44.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 42.2, implying annual growth of 16.4%.
Current consensus DPS estimate is 25.8, implying a prospective dividend yield of 0.7%.
Current consensus EPS estimate suggests the PER is 92.2.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 26.70 cents and EPS of 52.00 cents.
At the last closing share price the estimated dividend yield is 0.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 74.79.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 50.0, implying annual growth of 18.5%.
Current consensus DPS estimate is 30.7, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 77.8.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

VYS    VYSARN LIMITED

Industrial Sector Contractors & Engineers – Overnight Price: $0.58

Canaccord Genuity rates ((VYS)) as Buy (1) –

Following Canaccord Genuity’s acquisition of Wilsons, Vysarn continues to be covered by James Ferrier.

Buy. Target Price $0.64.

This report was published on October 3, 2025.

Target price is $0.64 Current Price is $0.58 Difference: $0.06
If VYS meets the Canaccord Genuity target it will return approximately 10% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.71.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.13.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

Click to view our Glossary of Financial Terms